David Bellovin
Vice President, Discovery and Translational Biology @ Attovia Therapeutics
About
I am currently working as the Vice President of Translational Biology at Attovia Therapeutics. In my current position, I am working to bring forward new therapeutics for diseases in Immunology and Inflammation. I have spent the last 21 years performing basic and translational research in the fields of cancer biology and immunology. I obtained my PhD investigating the mechanisms of colorectal and breast cancer cell invasion upon EMT. Subsequently, I spent six years developing primary mouse models of hepatocellular carcinoma, studying disease onset, progression, imaging, and metastasis. During this time, I also dedicating my efforts towards elucidating the progression and treatment of lymphoma, as well as kidney, lung, and bone cancers. Since moving to industry, my initial focus was on the development and utilization of preclinical animal models to support the discovery and development of novel therapeutics in cancer and immuno-oncology. More recently, I have begun overseeing groups responsible for identifying and validating new targets in various areas of oncology and immunology, while continuing to manage in vivo pharmacology and preclinical development to support our multiple pre-IND therapeutics and translational biology to provide insight into the activity of these therapeutics in patients.
United States
San Jose
Pharmaceuticals
Immuno-Oncology, Cancer Research, Drug Development, Pre-clinical Studies, Animal Models, Pharmacology, In Vivo, Cancer, Cell Biology, Cell, Immunohistochemistry, Signal Transduction, Molecular Biology, Tissue Culture, Life Sciences, Cell Culture, Fluorescence Microscopy, Genetics, Molecular Cloning, qPCR
Experience
Vice President, Discovery and Translational Biology
Attovia Therapeutics
Fremont, California, United States
Vice President, Discovery Biology and Pharmacology
Alamar Biosciences, Inc.
Fremont, California, United States
Senior Director, Head of Biology, Oncology Discovery
Zai Lab
Menlo Park, California, United States
Director, Head of In Vivo Pharmacology
Zai Lab
Menlo Park, CA
Director, Pharmacology
Five Prime Therapeutics, Inc.
South San Francisco, California
Associate Director, Pharmacology
Five Prime Therapeutics, Inc.
South San Francisco, CA
Senior Scientist
Five Prime Therapeutics, Inc.
South San Francisco, CA
Scientist III
Five Prime Therapeutics, Inc.
South San Francisco, California
My primary responsibilities include leading an in vivo discovery effort to identify novel immunity-oncology targets and examining the efficacy and mechanism of action of unique combinations of immune-oncology therapeutics using syngeneic tumor models.
Scientist II
Five Prime Therapeutics
South San Francisco, CA
I am currently working in Pharmacology, specializing in the development of preclinical models to examine the efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of our growing pipeline of anti-cancer therapeutics.
Instructor, Department of Medicine
Stanford University School of Medicine
Stanford, CA
My postdoctoral work was focused primarily on characterizing the mechanisms governing liver cancer metastasis using novel primary transgenic mouse models of hepatocellular carcinoma (HCC). In addition, I investigated the contribution of multiple independent genes to HCC onset and assisting in the coordination of a collaboration with a local biopharmaceutical company to design anti-cancer therapies. I also worked to investigate the mechanisms underlying onset and therapy of lymphoma as well as kidney, lung, and bone cancers using a variety of mouse models and novel imaging modalities.
Postdoctoral Fellow
Stanford University
During my postdoctoral research, I developed two novel primary mouse models of liver cancer metastasis, which I am continuing to investigate. In addition, my postdoctoral work included the identification of multiple genes and chemicals that can facilitate liver cancer onset, characterization of the anti-tumorigenic properties of Atorvastatin in HCC, and coordinating a collaboration with a local biopharmaceutical company to develop novel anti-cancer therapies.
Graduate Student
Harvard Medical School
My graduate work was primarily focused on investigating the role of the epithelial adhesion protein p120ctn in the epithelial-to-mesenchymal transition (EMT) of colorectal carcinoma. Additional work during my Ph.D. included studying the contributions of the RhoC small GTPase and integrin beta-6 to the progression of colorectal carcinoma using the EMT as a model.
Undergraduate Researcher
University of Arizona
Education
Harvard Medical School
Experimental Pathology/Cancer Biology
Ph.D. earned in the laboratory of Dr. Arthur Mercurio, Department of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center (currently Vice Chairman of the Department of Cancer Biology at the University of Massachusetts Medical School).
Stanford University School of Medicine
Mouse Models of Cancer
University of Arizona
Biochemistry, Molecular and Cellular Biology
Worked as an undergraduate researcher in the laboratory of Dr. David Galbraith, Dept. of Plant Sciences, studying drought response in arabidopsis.
David Bellovin's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.